FeesSafety
Pluang+

Fate Therapeutics appoints Jamie Harrell to lead commercialization of CAR T-cell therapies for autoimmune diseases.

Market News
12 Oct 2026, 18:00 WIB
Na
View Source
Bullish
Fate Therapeutics appoints Jamie Harrell to lead commercialization of CAR T-cell therapies for autoimmune diseases.

Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus nephritis and rheumatoid arthritis. Harrell brings over 25 years of commercial leadership, with experience launching breakthrough autoimmune treatments and expanding access through outpatient settings. His role will focus on advancing Fate's therapies from clinical trials to market, aiming to broaden patient access in community healthcare settings. This strategic hire supports Fate's goal to transform autoimmune disease treatment with innovative, off-the-shelf cellular immunotherapies.

Fate Therapeutics' strategic leadership update coincides with a mixed performance among health-sector stocks on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 12, 2026 18:11 WIB: out of 128 priced health-sector US stocks, 60 rose and 45 fell. Notable movers include ABCL (AbCellera Biologics Inc) up 1.55% at USD 12.74, NVAX (Novavax Inc) down 1.80% at USD 12.52, and CTXR (Citius Pharmaceuticals Inc) down 1.86% at USD 0.49, with typical hold times ranging from 17 to 59 days on Pluang.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
24 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
28 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
33 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
33 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
33 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App